Charalampos (Haris) Tzoulis's picture

Charalampos (Haris) Tzoulis

Professor, Professor of Neurology & Neurogenetics
  • E-mailCharalampos.Tzoulis@uib.no
  • Visitor Address
    Department of Neurology, Haukeland University Hospital
    Telephone: +47 55975045
  • Postal Address
    Postboks 7804
    5020 Bergen

Charalampos Tzoulis is Professor of Neurology and Neurodegeneration. He is Director of the research group Neuromics at the University of Bergen and CoDirector of the Neuro-SysMed Center of Excellence for Clinical Treatment Research in Neurological Diseases, where he leads the research on Parkinson's disease. For more information visit the website of the Neuromics Research Group: http://www.neuromics.org/ and the Neuro-SysMed Center: https://neuro-sysmed.no/ 

  • Show author(s) 2021. The impact of common genetic variants in cognitive decline in the first seven years of Parkinson's disease: A longitudinal observational study. Neuroscience Letters. 1-7.
  • Show author(s) 2021. Stem cell derived astrocytes with POLG mutations and mitochondrial dysfunction including abnormal NAD+ metabolism is toxic for neurons. BioRxiv.
  • Show author(s) 2021. NSAID use is not associated with Parkinson's disease incidence: A Norwegian Prescription Database study. PLOS ONE.
  • Show author(s) 2021. Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain. Molecular Neurodegeneration. 1-20.
  • Show author(s) 2021. Base excision repair causes age-dependent accumulation of single-stranded DNA breaks that contribute to Parkinson disease pathology. Cell reports. 1-44.
  • Show author(s) 2020. Using urine to diagnose large-scale mtDNA deletions in adult patients. Annals of clinical and translational neurology. 1318-1326.
  • Show author(s) 2020. Targeting NAD+ in translational research to relieve diseases and conditions of metabolic stress and ageing. Mechanisms of Ageing and Development. 1-6.
  • Show author(s) 2020. Mitochondrial respiratory chain deficiency correlates with the severity of neuropathology in sporadic Creutzfeldt-Jakob disease. Acta neuropathologica communications. 1-13.
  • Show author(s) 2020. Meta-analysis of whole-exome sequencing data from two independent cohorts finds no evidence for rare variant enrichment in Parkinson disease associated loci. PLOS ONE. 1-9.
  • Show author(s) 2020. LIVE@Home.Path--innovating the clinical pathway for home-dwelling people with dementia and their caregivers: Study protocol for a mixed-method, stepped-wedge, randomized controlled trial. Trials. 1-16.
  • Show author(s) 2020. Disease-specific phenotypes in iPSC-derived neural stem cells with POLG mutations. EMBO Molecular Medicine. 1-26.
  • Show author(s) 2020. Differential transcript usage in the Parkinson’s disease brain. PLoS Genetics. 1-24.
  • Show author(s) 2020. Common gene expression signatures in Parkinson’s disease are driven by changes in cell composition. Acta neuropathologica communications. 1-14.
  • Show author(s) 2019. Poly-ADP-ribose assisted protein localization resolves that DJ-1, but not LRRK2 or α-synuclein, is localized to the mitochondrial matrix. PLOS ONE. 1-14.
  • Show author(s) 2019. Mitochondrial mechanisms in neurodegeneration.
  • Show author(s) 2019. Mitochondrial DNA depletion in sporadic inclusion body myositis. Neuromuscular Disorders. 242-246.
  • Show author(s) 2018. Ultradeep mapping of neuronal mitochondrial deletions in Parkinson's disease. Neurobiology of Aging. 120-127.
  • Show author(s) 2018. Rare genetic variation in mitochondrial pathways influences the risk for parkinson's disease. Movement Disorders. 1591-1600.
  • Show author(s) 2018. Phenotype-genotype correlations in leigh syndrome: New insights from a multicentre study of 96 patients. Journal of Medical Genetics. 21-27.
  • Show author(s) 2018. No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson's disease. Brain. e16-e16.
  • Show author(s) 2018. Movement disorders in mitochondrial disease: a clinicopathological correlation. Current Opinion in Neurology. 472-483.
  • Show author(s) 2018. Dopaminergic and opioid pathways associated with impulse control disorders in Parkinson's disease. Frontiers in Neurology. 1-9.
  • Show author(s) 2018. Correction to: The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations (Genetics in Medicine, (2017), 19, 11, (1217-1225), 10.1038/gim.2017.35). Genetics in Medicine. 1-1.
  • Show author(s) 2018. Association of glucocerebrosidase polymorphisms and mutations with dementia in incident Parkinson's disease. Alzheimer's & Dementia. 1293-1301.
  • Show author(s) 2018. Alzheimer disease associated variants in SORL1 accelerate dementia development in Parkinson disease. Neuroscience Letters. 123-126.
  • Show author(s) 2018. 3,3'-Diaminobenzidine staining interferes with PCR-based DNA analysis. Scientific Reports. 1-8.
  • Show author(s) 2017. The angiogenic switch leads to a metabolic shift in human glioblastoma. Neuro-Oncology. 383-393.
  • Show author(s) 2017. Simvastatin is associated with decreased risk of Parkinson disease. Annals of Neurology. 329-330.
  • Show author(s) 2017. PNKP Mutations Identified by Whole-Exome Sequencing in a Norwegian Patient with Sporadic Ataxia and Edema. Cerebellum. 272-275.
  • Show author(s) 2017. No evidence of ischemia in stroke-like lesions of mitochondrial POLG encephalopathy. Mitochondrion (Amsterdam. Print). 10-15.
  • Show author(s) 2017. Neuronal complex I deficiency occurs throughout the Parkinson's disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage. Acta Neuropathologica. 409-425.
  • Show author(s) 2017. Multippel sklerose - en mitokondriemediert sykdom? Tidsskrift for Den norske legeforening. 274-287.
  • Show author(s) 2017. In vitro characterization of six STUB1 variants in spinocerebellar ataxia 16 reveals altered structural properties for the encoded CHIP proteins. Bioscience Reports. 1-12.
  • Show author(s) 2017. High-resolution subcellular localization of pathogenic proteins in Parkinson's disease.
  • Show author(s) 2017. Glitazone use associated with reduced risk of Parkinson's disease. Movement Disorders. 1594-1599.
  • Show author(s) 2017. Familial aggregation of Parkinson's disease may affect progression of motor symptoms and dementia. Movement Disorders. 241-245.
  • Show author(s) 2016. Subcellular Parkinson’s disease-specific alpha-synuclein species show altered behavior in neurodegeneration. Molecular Neurobiology. 1-17.
  • Show author(s) 2016. Novel SLC19A3 promoter deletion and allelic silencing in biotin-thiamine-responsive basal ganglia encephalopathy. PLOS ONE.
  • Show author(s) 2016. Nigrostriatal denervation sine parkinsonism. Brain.
  • Show author(s) 2016. Mitochondrial DNA homeostasis is essential for nigrostriatal integrity. Mitochondrion (Amsterdam. Print). 33-37.
  • Show author(s) 2016. Management of dystonia in Europe: A survey of the European network for the study of the dystonia syndromes. European Journal of Neurology. 772-779.
  • Show author(s) 2016. Increased levels of cell-free mitochondrial DNA in the cerebrospinal fluid of patients with multiple sclerosis. Mitochondrion (Amsterdam. Print). 32-35.
  • Show author(s) 2016. Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nature Communications. 11 pages.
  • Show author(s) 2016. ADCK3 mutations with epilepsy, stroke-like episodes and ataxia: a POLG mimic? European Journal of Neurology. 1188-1194.
  • Show author(s) 2015. Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. Journal of Neurology. 2201-2213.
  • Show author(s) 2015. HTRA2 p.G399S in Parkinson disease, essential tremor, and tremulous cervical dystonia. Proceedings of the National Academy of Sciences of the United States of America.
  • Show author(s) 2015. Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report. BMC Research Notes. 1-5.
  • Show author(s) 2015. En mann i 50-årene med høyt ferritinnivå og økende kognitiv svikt. Tidsskrift for Den norske legeforening. 1369-1372.
  • Show author(s) 2015. En kvinne i 70-årene med langvarige gangvansker. Tidsskrift for Den norske legeforening.
  • Show author(s) 2014. Spastic paraplegia type 7 is associated with multiple mitochondrial DNA deletions. PLOS ONE.
  • Show author(s) 2014. Myoclonus-dystonia and epilepsy in a family with a novel epsilon-sarcoglycan mutation. Journal of Neurology. 358-362.
  • Show author(s) 2014. Molecular pathogenesis of polymerase gamma-related neurodegeneration. Annals of Neurology. 66-81.
  • Show author(s) 2014. A multicenter study on Leigh syndrome: Disease course and predictors of survival. Orphanet Journal of Rare Diseases.
  • Show author(s) 2013. Severe nigrostriatal degeneration without clinical parkinsonism in patients with polymerase gamma mutations. Brain. 2393-2404.
  • Show author(s) 2013. Progressive striatal necrosis associated with anti-NMDA receptor antibodies. BMC Neurology. 4 pages.
  • Show author(s) 2013. Novel SACS mutations identified by whole exome sequencing in a Norwegian family with autosomal recessive spastic ataxia of Charlevoix-Saguenay. PLOS ONE. 5 pages.
  • Show author(s) 2013. MRI characterisation of adult onset alpha-methylacyl-coA racemase deficiency diagnosed by exome sequencing. Orphanet Journal of Rare Diseases. 10 pages.
  • Show author(s) 2012. Polymerase gamma (POLG) associated encephalopathy is characterised by neuronal mtDNA depletion and respiratory complex-I deficiency. European Journal of Neurology. 63-63.
  • Show author(s) 2012. Number of CAG repeats in POLG1 and its association with Parkinson disease in the Norwegian population. Mitochondrion (Amsterdam. Print). 640-643.
  • Show author(s) 2012. Leukoencephalopathy with brainstem and spinal cord involvement caused by a novel mutation in the DARS2 gene. Journal of Neurology. 292-296.
  • Show author(s) 2012. Leukoencephalopathy with brainstem and spinal cord involvement and elevated lactate (LBSL) caused by a novel mutation in DARS2. European Journal of Neurology. 728-728.
  • Show author(s) 2012. Erdheim-Chester disease presenting with an intramedullary spinal cord lesion. Journal of Neurology. 2240-2242.
  • Show author(s) 2012. Acute mitochondrial encephalopathy reflects neuronal energy failure irrespective of which genome the genetic defect affects. Brain. 3627-3634.
  • Show author(s) 2011. Defining the mitochondrial POLG-related spinocerebellar ataxia and epilepsy in Norway. Advances in Clinical Neurosciences. 20-21.
  • Show author(s) 2010. Localized cerebral energy failure in mitochondrial polymerase gamma-associated encephalopathy. European Journal of Neurology. 71-71.
  • Show author(s) 2010. Localized cerebral energy failure in DNA polymerase gamma-associated encephalopathy syndromes. Brain. 1428-1437.
  • Show author(s) 2010. Differences in RNA processing underlie the tissue specific phenotype of ISCU myopathy. Biochimica et Biophysica Acta - Molecular Basis of Disease. 539-544.
  • Show author(s) 2010. Clinical and molecular studies of disease caused by mutations of the mitochondrial DNA polymerase gamma (POLG).
  • Show author(s) 2009. Serial Diffusion Imaging in a Case of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes. Stroke. E15-E17.
  • Show author(s) 2009. RNA processing differences explain tissue specificity in exercise intolerance myopathy due to ISCU intronic mutation. Neuromuscular Disorders. 623-623.
  • Show author(s) 2009. Neuropsychological performance of patients with polg1 mutation and epilepsy: evidence of more pronounced right than left hemisphere dysfunction? Epilepsia. 119-119.
  • Show author(s) 2009. Neuropsychological performance in patients with POLG1 mutations and the syndrome of mitochondrial spinocerebellar ataxia and epilepsy. Epilepsy & Behavior. 172-174.
  • Show author(s) 2009. Mitochondrial DNA depletion in progressive external ophthalmoplegia caused by POLG1 mutations. Acta Neurologica Scandinavica. 38-41.
  • Show author(s) 2009. MRI and neuropathology findings in three patients with the syndrome of mitochondrial spinocerebellar ataxia and epilepsy (MSCAE). Neuropathology and Applied Neurobiology. 20-20.
  • Show author(s) 2008. POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain. 818-828.
  • Show author(s) 2008. Hereditary spastic paraplegia caused by the novel mutation 1047insC in the SPG7 gene. Journal of Neurology. 1142-1144.
  • Show author(s) 2007. MELAS associated with mutations in the POLG1 gene. Neurology.
  • Show author(s) 2007. Hereditary spastic paraplegia caused by the novel mutation 1047INSC in the SPG7 gene. European Journal of Neurology. 240-240.
  • Show author(s) 2007. Cerebral imaging in mitochondrial spinocerebellar ataxia caused by POLG mutations shows diagnostic specificity and provides insight into disease evolution. European Journal of Neurology. 14-15.
  • Show author(s) 2006. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain. 1685-1692.
  • Show author(s) 2006. The clinical spectrum of disease in 26 patients with G1399A or G2243C mutations in the gene encoding the catalytic subunit of mitochondrial DNA-polymerase gamma. European Journal of Neurology. 40-40.
  • Show author(s) 2006. The clinical semiology of epilepsy in patients with mitochondriopathy due to polymerasegamma-(POLG) mutations. Epilepsia. 248-248.

More information in national current research information system (CRIStin)